Sign In
Buy TRVN
$0.0010
+0 (+0%)
At Close: Jun 03, 2026
-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy
07:00am, Friday, 20'th Nov 2020
-- OLINVYK s ignificantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis
Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
12:42pm, Monday, 09'th Nov 2020
OLINVYK is headed for commercial availability, likely by Q1 '21, even though distribution can occur as early as late November following DEA scheduling. Trevena still has a busy 2021 full of catalysts.
Trevena, Inc. to Participate in the Following November Virtual Investor Conferences
07:00am, Monday, 09'th Nov 2020
-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day Conference November 16 th Stifel Virtual Healthcare Conference November 1 8 th
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
07:44am, Friday, 30'th Oct 2020
-- OLINVYK commercial supply on track and available in November
